Role of Infliximab in Immune Checkpoint Inhibitor-Induced Pneumonitis

Introduction: Since immune checkpoint inhibitor (ICI) blockade has become standard therapy for many cancers, immune-related adverse events (irAEs) have increased. ICI-pneumonitis is infrequent but potentially fatal. In cases not responsive to corticosteroids, additional immunosuppression is recommen...

Full description

Bibliographic Details

Published in:	Journal of Immunotherapy and Precision Oncology
Main Authors:	Kathryn A. Lai, Ajay Sheshadri, Andres M. Adrianza, Mikel Etchegaray, Diwakar D. Balachandran, Lara Bashoura, Vickie R. Shannon, Saadia A. Faiz
Format:	Article
Language:	English
Published:	Innovative Healthcare Institute 2020-11-01
Subjects:	immunotherapy cancer anti-pd-1 infliximab immune-related adverse events pneumonitis
Online Access:	https://jipo.org/doi/pdf/10.36401/JIPO-20-22